ESS team is trash

Full of shit, you can talk off label!
The higher standard is my foot up your big ass!!!

 

More time and money is invested into us ESS. We are specialty. You are primary. Know your role.

 

I have no problem that a specialty force exists and the idea of having many of our best diabetes reps calling on them is fantastic. But they didn't do it right. They shouldn't have created overlay territories, but instead split them in half and given everyone true ownership of fewer accounts.

Then, they should have left forward thinking FP/GP/IM physicians who actually use a fair amount of non-insulin injectable medicines out of their universe, so that we could more clearly see growth at the true specialists. Essentially, If we want to grow our gravitas and sales with endos, then call on endos and understand that it is a long-term proposition - not something that will be achieved in 6 or 12 months.

We have little endo growth here and what growth there is can be attributed to reps who have been working with the same customers for a long time. Not somebody from 2 hours away who can get in to the office once a month. Unfortunately, we're now in a situation where everyone is trying to figure out how to keep there jobs, not how to do the best job.

With that kind of culture, ESS won't end well.

 

ESS was a short sighted approach to a long term goal. We will do well when it is put to bed. Nobody sees value in this format. Employee or customer the same.

 

I've not met a single person who thinks ESS is/was a good idea. This is such a joke and waste of time and money. I guess in that regard, it makes perfect sense.

 

Aside from the fact the number of scripts are down for the endos in my territory, my ESS "partners" have not "expanded the base". They haven't gotten one single new target Endo to prescribe either Farxiga or Bydureon since they started. Just sayin'.

 

Same case in my territory, no new endos are writing, the same ones who were speakers to be begin with are generating some business. I would not care except that this is killing my numbers. I have showed my manager that I have increased business in all of my Top 10 primary care physicians but my numbers are still down because the endos ( which I am not responsible for) are down and flat.

 

Same here. The only endos that rx are the ones DSS had prescribing earlier. ESS hasn't achieved one new writer across the board. Simply riding the wave DSS already created.

 

ESS.
Ever-increasing shitty sales.

 

When will they do away with this force? By the sounds of things, it is pretty clearly a major failure.

 

Your docs are now my docs. ESS runs the show. We control the specialists and the volume. We control the budgets. We control the speakers. We control you. Deal with it. Get used to it.

 

I wondered what it was you were doing all this time. Thanks for clarifying. And controlling.

 

ESS is expanding. If you can't beat us, join us.

 

My top customer doesn't even know my specialists name. Literally. This is a sad state of affairs. This will end badly for all of us. Millions of dollars in lost sales are on the line. And that puts us all in jeopardy.

 

This thread has only been around for 4 months, has almost 200 posts, and over 25,000 views.

This clearly is a hot, much contested and debated topic.

Open your eyes, management!

 

Spot on. We are ALL in jeopardy due to this failure. Some times leadership is admitting a mistake and correcting it before it's too late.

 

For all in ESS that say this is whining or just back-biting bullshit, here is an exercise for you. Go to iPerform. Pull up the Farxiga page and make sure to click on that button that brings up the Invokana trend line. Take a look at it first for "all" targets, then look at it with only "endo" selected. Then do the same for "IM" and "PCP." After that do the same for Bydyreon. The Data don't lie. In the VAST majority of territories the trend line for Farxiga is going up and Invokana is going down, the gap is narrowing - EXCEPT in the endo space. Same with Bydureon compared to Victoza. IM and PCP targets are driving growth while you jackasses are playing some shell game attaching our numbers to your "success stories." I urge you all reading this to check out the trending for yourselves. In my territory it was an eye opener. What a joke. Separate out the IC now PLEASE.

 

You nailed it. And the only endos that are writing in my district are those with a strong previous DSS relationship.

 

Same here. ESS has had a negative net impact. A big negative, and an ever growing negative. It's officially a downward trend and it's not looking pretty.

 

"shell game" pretty much nails it, someone called it a Ponzi scheme too. It is a joke. Thanks for the tip, never looked at it that way specifically. The endo trend line is slowly dropping for Bydureon in my geography, Farxiga never off the ground. i would not care, but these guys are driving my comp plan down into the 70% to goal range. pissed